Arax Advisory Partners’s Avanos Medical AVNS Stock Holding History

Arax Advisory Partners’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$140K	Buy	5,639 +4,649	+470%	+$109K	﹤0.01%	2494
2026 Q1	$13.9K	Buy	990 +86	+10%	+$1.16K	﹤0.01%	2274
2025 Q4	$10.2K	Sell	904 -12,848	-93%	-$147K	﹤0.01%	2460
2025 Q3	$159K	Buy	13,752 +12,146	+756%	+$142K	﹤0.01%	1348
2025 Q2	$19.7K	Buy	+1,606	New	+$20.2K	﹤0.01%	1675
2024 Q4	–	Sell	-74	Closed	-$1.78K	–	2462
2024 Q3	$1.78K	Hold	74	–	–	﹤0.01%	2105
2024 Q2	$1.48K	Buy	+74	New	+$1.44K	﹤0.01%	2058
2022 Q3	–	Sell	-26	Closed	-$1K	–	1209
2022 Q2	$1K	Hold	26	–	–	﹤0.01%	1006
2022 Q1	$1K	Hold	26	–	–	﹤0.01%	994
2021 Q4	$1K	Hold	26	–	–	﹤0.01%	969
2021 Q3	$1K	Hold	26	–	–	﹤0.01%	876
2021 Q2	$1K	Buy	+26	New	+$1.07K	﹤0.01%	873
2020 Q4	$1K	Hold	26	–	–	﹤0.01%	688
2020 Q3	$1K	Hold	26	–	–	﹤0.01%	654
2020 Q2	$1K	Hold	26	–	–	﹤0.01%	641
2020 Q1	$1K	Hold	26	–	–	﹤0.01%	640
2019 Q4	$1K	Hold	26	–	–	﹤0.01%	560
2019 Q3	$1K	Hold	26	–	–	﹤0.01%	562
2019 Q2	$1K	Buy	+26	New	+$1.11K	﹤0.01%	566

Other funds holding AVNS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.5B AUM 83.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Arax Advisory Partners's AVNS Position: Q2 2026 in Review

Arax Advisory Partners increased its Avanos Medical (AVNS) stake by 470% in Q2 2026, buying an estimated $109K and bringing the position to 5,639 shares worth $140K. The position accounts for ﹤0.01% of the portfolio, ranked #2494.

Arax Advisory Partners first reported a position in AVNS in Q2 2019 and has held it in 19 quarters since. The position peaked at $159K in Q3 2025. 286 funds tracked by Wall St. Rank hold AVNS as of Q2 2026.

Arax Advisory Partners held 5,639 shares of Avanos Medical worth $140K as of Q2 2026.
Arax Advisory Partners bought 4,649 Avanos Medical shares in Q2 2026, an estimated $109K.
Avanos Medical made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2494 holding.
Arax Advisory Partners first reported a position in Avanos Medical in Q2 2019 and has held it in 19 quarters since.
Arax Advisory Partners's Avanos Medical position peaked at $159K in Q3 2025.
286 funds tracked by Wall St. Rank held Avanos Medical as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.